NCCN Guidelines® Insights: Lung Cancer Screening, Version 1.2025. Read more about NCCN Guidelines® Insights: Lung Cancer Screening, Version 1.2025.
NCCN Guidelines® Insights: Survivorship, Version 2.2024. Read more about NCCN Guidelines® Insights: Survivorship, Version 2.2024.
Achieving Adherence With NCCN Guidelines for Nonmelanoma Skin Cancer Regarding Peripheral and Deep En Face Margin Assessment (PDEMA). Read more about Achieving Adherence With NCCN Guidelines for Nonmelanoma Skin Cancer Regarding Peripheral and Deep En Face Margin Assessment (PDEMA).
The Role of CAR T-Cell Therapy in Relapsed/Refractory Adult B-ALL. Read more about The Role of CAR T-Cell Therapy in Relapsed/Refractory Adult B-ALL.
Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Read more about Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Neuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Read more about Neuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Establishing Consensus for Mohs Micrographic Surgical Techniques in the Treatment of Melanoma in Situ for Future Clinical Trials: A Modified Delphi Study. Read more about Establishing Consensus for Mohs Micrographic Surgical Techniques in the Treatment of Melanoma in Situ for Future Clinical Trials: A Modified Delphi Study.
Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology Read more about Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology
NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024. Read more about NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024.
CRE24-034: Successful Management of Locally Advanced and Oligometastatic Urothelial Carcinoma With Pembrolizumab-Based Induction Regimen Followed by Consolidative Radical Resection of the Primary Tumor: A Multi-Institutional Case Series. Read more about CRE24-034: Successful Management of Locally Advanced and Oligometastatic Urothelial Carcinoma With Pembrolizumab-Based Induction Regimen Followed by Consolidative Radical Resection of the Primary Tumor: A Multi-Institutional Case Series.
